Hostname: page-component-6766d58669-vgfm9 Total loading time: 0 Render date: 2026-05-18T19:37:56.743Z Has data issue: false hasContentIssue false
  • English
  • Français

Reporting of harms in clinical trials of esketamine in depression: a systematic review

Published online by Cambridge University Press:  26 April 2023

Tanguy Taillefer de Laportalière Open the ORCID record for Tanguy Taillefer de Laportalière [Opens in a new window] ,
Adeline Jullien ,
Antoine Yrondi ,
Philippe Cestac  and
François Montastruc Open the ORCID record for François Montastruc [Opens in a new window]
Tanguy Taillefer de Laportalière*
Affiliation:
Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France
Adeline Jullien
Affiliation:
Department of Pharmacy, Toulouse University Hospital (CHU), Toulouse, France
Antoine Yrondi
Affiliation:
Department of Medical Psychiatry, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France Treatment Resistant Depression Expert Center, FondaMental, Toulouse, France ToNIC Toulouse NeuroImaging Center, University Paul Sabatier Toulouse, INSERM, Toulouse, France
Philippe Cestac
Affiliation:
Department of Pharmacy, Toulouse University Hospital (CHU), Toulouse, France
François Montastruc
Affiliation:
Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France Department of Medical Psychiatry, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France Centre d'Investigation Clinique 1436, Team PEPSS ‘Pharmacologie En Population cohorteS et biobanqueS’, Toulouse University Hospital, France
*
Corresponding author: Tanguy Taillefer de Laportalière, E-mail: tailleferdelaportaliere.t@chu-toulouse.fr
Get access Rights & Permissions [Opens in a new window]

Abstract

While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression. The objective of this review was to assess quality of reporting AEs in all published clinical trials studying esketamine. It also aimed to compare the proportions of AEs reported in journal articles to those recorded in the ClinicalTrial.gov Registers. Clinical trials evaluating the efficacy and safety of esketamine in depression were searched using Medline and ClinicalTrials.gov. The quality of reporting harms was assessed using a 21-item checklist from the CONSORT Extension of Harms (1 point by item). The total quality score was graded into four categories: high (17–21), moderate (12–16), low (7–11) and very low (0–6). Ten clinical trials were included in the analysis. Nine trials were classified as ‘low quality’ with regard to safety, one trial was classified as ‘moderate quality’. Compared to AEs recorded in ClinicalTrials.gov, we found that 41.5% of serious AEs and 39% of non-serious AEs were not reported in the published articles. Among them, the majority were psychiatric events but also cardiovascular events and 94% concerned patients from esketamine groups. Quality of AEs reporting in published clinical trials of esketamine was poor and harms were reported less frequently in journal publications than in ClinicalTrial.gov Registers. The study suggests that an assessment of the benefits/risks balance of esketamine based on the results reported in trial publications is flawed due to the poor accuracy and completeness of harm data.

Keywords

Adverse eventesketaminequality of reportingtreatment-resistant depression

Information

Type
Review Article
Information
Psychological Medicine , Volume 53 , Issue 10 , July 2023 , pp. 4305 - 4315
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., … Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. The American Journal of Psychiatry, 175(7), 620–630. doi:10.1176/appi.ajp.2018.17060720CrossRefGoogle ScholarPubMed
Capuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., … Dakanalis, A. (2021). Long-term efficacy of intranasal esketamine in treatment-resistant major depression: A systematic review. International Journal of Molecular Sciences, 22(17), 9338. doi:10.3390/ijms22179338CrossRefGoogle ScholarPubMed
ClinicalTrials.gov. (2018). About the results database. Retrieved from https://clinicaltrials.gov/ct2/about-site/results. Accessed 14 December 2022.Google Scholar
Cristea, I. A., & Naudet, F. (2019). US Food and Drug Administration approval of esketamine and brexanolone. The Lancet. Psychiatry, 6(12), 975–977. doi:10.1016/S2215-0366(19)30292-5CrossRefGoogle ScholarPubMed
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., … Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75(2), 139–148. doi:10.1001/jamapsychiatry.2017.3739CrossRefGoogle ScholarPubMed
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., … Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893–903. doi:10.1001/jamapsychiatry.2019.1189CrossRefGoogle ScholarPubMed
European Medical Agency (EMA). (2019). Assessment report Spravato. Retrieved from https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf. Accessed 23 June 2022.Google Scholar
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., … Singh, J. B. (2019). Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). The International Journal of Neuropsychopharmacology, 22(10), 616–630. doi:10.1093/ijnp/pyz039CrossRefGoogle ScholarPubMed
Fu, D. J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., … Canuso, C. M. (2020). Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (ASPIRE I). The Journal of Clinical Psychiatry, 81(3), 19m13191. doi:10.4088/JCP.19m13191CrossRefGoogle ScholarPubMed
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021). Post-marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychotherapy and Psychosomatics, 90(1), 41–48. doi:10.1159/000510703CrossRefGoogle ScholarPubMed
Horowitz, M. A., & Moncrieff, J. (2021). Are we repeating mistakes of the past? A review of the evidence for esketamine. The British Journal of Psychiatry: the Journal of Mental Science, 219(5), 614–617. doi:10.1192/bjp.2020.89CrossRefGoogle Scholar
Ioannidis, J. P., Evans, S. J., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., & Schulz, K., … CONSORT Group (2004). Better reporting of harms in randomized trials: An extension of the CONSORT statement. Annals of Internal Medicine, 141(10), 781–788. doi:10.7326/0003-4819-141-10-200411160-00009CrossRefGoogle ScholarPubMed
Ioannidis, J. P., & Lau, J. (2001). Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA, 285(4), 437–443. doi:10.1001/jama.285.4.437CrossRefGoogle ScholarPubMed
Ionescu, D. F., Fu, D. J., Qiu, X., Lane, R., Lim, P., Kasper, S., … Canuso, C. M. (2021). Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a phase 3, double-blind, randomized study (ASPIRE II). The International Journal of Neuropsychopharmacology, 24(1), 22–31. doi:10.1093/ijnp/pyaa068CrossRefGoogle ScholarPubMed
Kow, C. S., Aldeyab, M., & Hasan, S. S. (2021). Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19. European Journal of Clinical Pharmacology, 77(3), 435–437. doi:10.1007/s00228-020-03008-6CrossRefGoogle ScholarPubMed
Kryst, J., Kawalec, P., & Pilc, A. (2020). Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy, 21(1), 9–20. doi:10.1080/14656566.2019.1683161CrossRefGoogle ScholarPubMed
Mazhar, F., Hadi, M. A., Kow, C. S., Marran, A., Merchant, H. A., & Hasan, S. S. (2020). Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 101, 107–120. doi:10.1016/j.ijid.2020.09.1470Google ScholarPubMed
Meister, R., von Wolff, A., Mohr, H., Nestoriuc, Y., Härter, M., Hölzel, L., & Kriston, L. (2016). Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder. Journal of Clinical Epidemiology, 71, 97–108. doi:10.1016/j.jclinepi.2015.10.007CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (NICE). (2020 February 18). Esketamine for treating treatment-resistant depression. Retrieved from https://www.nice.org.uk/consultations/839/1/recommendations#recommendations. Accessed 23 June 2022.Google Scholar
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., … Singh, J. B. (2020). Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. The American Journal of Geriatric Psychiatry, 28(2), 121–141. doi:10.1016/j.jagp.2019.10.008CrossRefGoogle ScholarPubMed
Papanikolaou, P. N., Churchill, R., Wahlbeck, K., & Ioannidis, J. P. (2004). Safety reporting in randomized trials of mental health interventions. The American Journal of Psychiatry, 161(9), 1692–1697. doi:10.1176/appi.ajp.161.9.1692CrossRefGoogle ScholarPubMed
Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., … Blier, P. (2020). Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, 45(4), 606–612. doi:10.1038/s41386-019-0570-xCrossRefGoogle ScholarPubMed
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., … Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. The American Journal of Psychiatry, 176(6), 428–438. doi:10.1176/appi.ajp.2019.19020172CrossRefGoogle ScholarPubMed
Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332. doi:10.1136/bmj.c332CrossRefGoogle ScholarPubMed
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., … Higgins, J. P. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919. doi:10.1136/bmj.i4919CrossRefGoogle ScholarPubMed
Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., … Higgins, J. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. doi:10.1136/bmj.l4898CrossRefGoogle ScholarPubMed
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021). Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: A phase 2b randomized clinical study. BMC Psychiatry, 21(1), 526. doi:10.1186/s12888-021-03538-yCrossRefGoogle ScholarPubMed
Turner, E. H. (2019). Esketamine for treatment-resistant depression: Seven concerns about efficacy and FDA approval. The Lancet. Psychiatry, 6(12), 977–979. doi:10.1016/S2215-0366(19)30394-3CrossRefGoogle ScholarPubMed
US Food and Drug Administration (FDA). (2019). Briefing information for the February 12, 2019 joint meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM). Retrieved from https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM630970.pdf. Accessed 22 June 2022.Google Scholar
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., … Singh, J. B. (2020). Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). The Journal of Clinical Psychiatry, 81(3), 19m12891. doi:10.4088/JCP.19m12891CrossRefGoogle Scholar
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., … Kim, E. (2022). Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the CONSORT criteria for reporting harms: A systematic review. Vaccines, 10(2), 313. doi:10.3390/vaccines10020313CrossRefGoogle Scholar
Zorzela, L., Loke, Y. K., Ioannidis, J. P., Golder, S., Santaguida, P., Altman, D. G., … PRISMAHarms Group (2016). PRISMA harms checklist: Improving harms reporting in systematic reviews. BMJ, 352, i157. doi:10.1136/bmj.i157CrossRefGoogle ScholarPubMed
Supplementary material: File

Taillefer de Laportalière et al. supplementary material

Table S1 and Figure S1

Download Taillefer de Laportalière et al. supplementary material(File)
File 38.7 KB